Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adherex Technologies, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists
Clinically or radiologically documented measurable disease.
Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue
Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG)
You may not be if
Receipt of ADH-1 prior to this clinical study
Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry
History of primary brain tumors or brain metastases
History of spinal cord compression or tumors that have shown any evidence of active bleeding within 30 days before study entry.
Stroke, major surgery, or other major tissue injury within 30 days before study entry
History of congestive heart failure, myocardial infarction, angina, life threatening arrhythmias, significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states
Clareo Health | A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
